Pre-made Sevirumab benchmark antibody (Whole mAb, anti-HCMV (human cytomegalovirus) envelope glycoprotein H (gH) [Human betaherpesvirus 5] therapeutic antibody) for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-INN-989

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Product Details

Anti-HCMV (human cytomegalovirus) envelope glycoprotein H (gH) [Human betaherpesvirus 5] therapeutic antibody (Pre-made Sevirumab biosimilar, Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Sevirumab (MSL-19) is a human monoclonal antibody for the treatment of infections with cytomegalovirus in patients with AIDS.[1][2]

Products Name (INN Index)

Pre-Made Sevirumab Biosimilar, Whole Mab: Anti-Hcmv (Human Cytomegalovirus) Envelope Glycoprotein H (Gh) [Human Betaherpesvirus 5] therapeutic antibody

INN Name

sevirumab

Target

HCMV (human cytomegalovirus) envelope glycoprotein H (gH) [Human betaherpesvirus 5]

Format

Whole mAb

Derivation

Human

Species Reactivity

Human

CH1 Isotype

IgG1 – kappa

VD LC

IgG1 – kappa

Highest_Clin_Trial (Jan '20)

NA

Est. Status

NA

100% SI Structure

NA

99% SI Structure

NA

95-98% SI Structure

NA

Year Proposed

NA

Companies

Novartis Pharmaceuticals Corp. (East Hanover NJ USA) / PDL?(Protein Design?Labs) BioPharma (Fremont CA USA)

Conditions Approved

NA

Conditions Active

NA

Conditions Discontinued

NA

Development Tech

NA

Previous Name

NA

Gm Offical Target Name

HCMV (human cytomegalovirus) envelope glycoprotein H (gH) [Human betaherpesvirus 5]

Package

, ,

Genemeidi Omicron Variant Products
test
Previous slide
Next slide